Maddi Hebebrand, MC, Associate Editor

Pediatric dermatology experiences a transformative shift, enhancing care for younger patients and expanding therapeutic options.

Discover the latest advancements in hidradenitis suppurativa therapies, including promising biologics and oral treatments reshaping patient care in 2025.

Erik Domingues leads a vital discussion on innovative vitiligo management, addressing treatment challenges and psychosocial impacts in diverse patient populations.

Michael O'Donoghue, MD, shares insights on actinic keratosis management, emphasizing personalized therapy strategies.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover effective treatment strategies for keloids and hypertrophic scars in skin of color, emphasizing personalized approaches and combination therapies.

Zasocitinib emerges as a promising oral therapy for psoriasis, achieving significant skin clearance and favorable safety in recent phase 3 trials.

Porter leads a dynamic roundtable on hidradenitis suppurativa, exploring innovative treatments and collaborative strategies for improved patient outcomes.

New research reveals that combining DecisionDx-UM and PRAME significantly enhances survival predictions for uveal melanoma.

The BLA is supported by phase 3 data demonstrating rapid skin clearance and sustained disease control in patients with GPP.

Experts discuss innovative, steroid-sparing treatments for pediatric atopic dermatitis, emphasizing personalized care and proactive management strategies.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

A meta-analysis of over 800,000 patients shows JAK inhibitors are generally as safe as TNF antagonists for various purposes.

Galderma initiates a pivotal study on nemolizumab, targeting Chronic Pruritus of Unknown Origin, aiming to provide relief for this challenging condition.

Explore the long-term efficacy and safety of ligelizumab for CSU, highlighting self-administration success and significant symptom control.

Discover how anatomical variations impact the minimal erythema dose in 308-nm excimer laser therapy for vitiligo in Asian patients.

Comprehensive patch testing is vital for accurately diagnosing various forms of dermatitis, improving patient care, and addressing public health challenges.

MediWound reveals clinical data showing NexoBrid significantly reduces pigmentation in traumatic tattoos from abrasions and blast injuries.

Explore the emotional and physical challenges of chronic hand eczema through a patient's journey and expert insights on empathetic care and innovative treatments.

Discover the efficacy and safety of topical roflumilast 0.3% for psoriasis, highlighting its rapid results and potential for sensitive skin areas.

Kymera Therapeutics reveals promising phase 1b results for KT-621, an oral STAT6 degrader, showing significant effects in moderate to severe atopic dermatitis.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

A study reveals high rates of intimate partner violence among women with psoriasis, linking it to poorer quality of life and increased PTSD symptoms.